SCHEMBL5045678

SCHEMBL5045678

CCOC(=O)c1nc(-c2cc(C(=O)NCC3CCCCC3)c(C)n2CC2CCCO2)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
HPGD P15428 6/20 0.41
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
EPHX2 P34913 1/20 0.39
LMNA P02545 2/20 0.39
FEN1 P39748 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KMT2A Q03164 2/20 0.38
RXFP1 Q9HBX9 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
MEN1 O00255 1/20 0.38
ALOX15 P16050 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046957 0.89 ALDH1A1 (0.41) ALDH1A1HPGDTSHRSMN1; SMN2TP53
SCHEMBL5046983 0.85 GSK3B (0.41) ALDH1A1HPGDSMN1; SMN2LMNAHTT
SCHEMBL5039350 0.85 HPGD (0.45) ALDH1A1HPGDTSHRSMN1; SMN2TP53
SCHEMBL5043901 0.84 MAPT (0.45) ALDH1A1HPGDSMN1; SMN2LMNAHTT
SCHEMBL5133261 0.84 ALDH1A1 (0.38) ALDH1A1HPGDTSHRSMN1; SMN2TP53
SCHEMBL5045675 0.83 ALDH1A1 (0.42) ALDH1A1HPGDTSHRSMN1; SMN2TP53
SCHEMBL5046853 0.82 CDC25A (0.59) ALDH1A1HPGDTSHRSMN1; SMN2LMNA
SCHEMBL5048540 0.81 ALDH1A1 (0.48) ALDH1A1HPGDTSHRSMN1; SMN2LMNA
SCHEMBL5047024 0.81 ALDH1A1 (0.46) ALDH1A1TSHRSMN1; SMN2TP53KMT2A
SCHEMBL5045879 0.81 KLKB1 (0.44) ALDH1A1HPGDEPHX2HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R ALDH1A1 959/4885HPGD 2000/4885TSHR 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.